The invention also comprises a pharmaceutical composition comprising a first antibody or {TAIL ~ an antigen binding fragment} thereof, and a second antibody, or an antigen binding fragment thereof, wherein {HEAD ~ the first antibody} is an antibody of the invention, and the second antibody is an antibody that neutralizes hCMV infection 
The invention also comprises a pharmaceutical composition comprising a first antibody or { TAIL ~ an antigen binding fragment } thereof , and a second antibody , or an antigen binding fragment thereof , wherein { HEAD ~ the first antibody } is an antibody of the invention , and the second antibody is an antibody that neutralizes hCMV infection
OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH TAIL TAIL TAIL TAIL TAIL TAIL TAIL TAIL OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH HEAD HEAD HEAD HEAD HEAD HEAD HEAD OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH